Scientists see AIDS vaccine within reach after decades
But a string of failed attempts - punctuated by a 2007 trial in which a Merck vaccine appeared to make people more vulnerable to infection, not less - cast a shadow over AIDS vaccine research that has taken years to dispel.
A 2009 clinical trial in Thailand was the first to show it was possible to prevent HIV infection in humans. Since then, discoveries have pointed to even more powerful vaccines using HIV-fighting antibodies. Now scientists believe a licensed vaccine is within reach.
"We know the face of the enemy," said Dr. Barton Haynes, of Duke University in Durham, North Carolina, and recent director of the Center for HIV AIDS Vaccine Immunology (CHAVI). The research consortium was funded by the National Institute of Allergy and Infectious Diseases (NIAID), founded in 2005 by the National Institutes of Health to identify and overcome roadblocks in the design of vaccines for the human immunodeficiency virus, which causes AIDS. NIAID's funding of CHAVI ended in June.
Unlike many viruses behind infectious disease, HIV is a moving target, constantly spitting out slightly different versions of itself, with different strains affecting different populations around the world. The virus is especially pernicious since it attacks the immune system, the very mechanism the body needs to fight back.
"The virus is far more crafty than we ever thought," said Haynes, who will outline progress in vaccine research at the International AIDS Society's 2012 conference being held in Washington from July 22-27.
FIRST SIGN OF HOPE
Thanks to drugs that can control the virus for decades, AIDS is no longer a death sentence. New infections have fallen by 21 percent since the peak of the pandemic in 1997 and advances in prevention - through voluntary circumcision programs, prevention of mother-to-child transmission and early treatment - promise to cut that rate even more.
Still, as many as 34 million people are infected with HIV worldwide. And with 2.7 million new infections in 2010 alone, experts say a vaccine is still the best hope for eradicating AIDS.
Teams have been working on a vaccine for nearly three decades, but it wasn't until RV144, the 2009 clinical trial involving more than 16,000 adults in Thailand, that researchers achieved any hint of success.
The test of a combination of two vaccines followed several big failures, including the stunning news that Merck's vaccine may have increased the risk of infection among men who were both uncircumcised and had prior exposure to the virus used in the vaccine.
"It had an extremely chilling effect on the whole field," said Colonel Nelson Michael, director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, which led the RV144 trial.
The Thai study tested Sanofi's ALVAC, a weakened canary pox virus used to sneak three HIV genes into the body, and AIDSVAX, a vaccine originally made by Roche Holding's Genentech that carried an HIV surface protein.
Both vaccines had poor showings in individual trials. Researchers were so convinced the Thai trial would fail that 22 scientists wrote an editorial in Science calling it a waste of money.
Then came the shocker. Results of the study published in 2009 showed the vaccine combination cut HIV infections by 31.2 percent. According to Michael and many other experts, the result was not big enough to be considered effective, but its impact on researchers was huge, says Wayne Koff, chief scientific officer of the International AIDS Vaccine Initiative (IAVI) based in New York.
An extensive analysis of the Thai trial published this year in the New England Journal of Medicine offered clues about why some volunteers responded.
The study, led by Haynes, scientists at Walter Reed and 25 other institutions, found men and women who were vaccinated made antibodies to a specific region of the virus's outer coat, suggesting this region provides an important vaccine target.
Preparations are under way for a follow-up trial testing beefed-up versions of the vaccines among heterosexuals in South Africa and men who have sex with men in Thailand.
Once again, the trial will use a Sanofi vaccine, but instead of AIDSVAX, researchers will use a different vaccine candidate with a boosting agent from Novartis.
Michael said it has been a major effort to secure new research partners and funding, including support from host countries, as well as to persuade rivals Novartis and Sanofi to work together. The teams still need to retool the vaccines to work in South Africa, where the strain of HIV is different.
"We're really working as fast as we can," said Michael, who expects large-scale effectiveness studies to start in 2016.
The hope is to have at least 50 percent effectiveness, a level that mathematical modelers say could have a major impact on the epidemic. Michael thinks this might be the pathway for getting the first HIV vaccine licensed, possibly by 2019.
Vaccine experts are equally excited about a vaccine that Michael's team is developing with Harvard University and Johnson & Johnson's Crucell unit, which uses weakened versions of a common cold virus and a smallpox virus.
A study published in February showed this vaccine protected monkeys from a virulent strain of HIV. Animals that did become infected after repeated exposure also had low levels of virus in their blood. Safety studies in human patients are just starting, with large-scale efficacy studies slated for 2016.
The current crop of vaccines is largely designed to train immune system cells known as T-cells to recognize and kill cells already infected with HIV. While these trials progress, scientists are working on even more advanced vaccines that activate powerful antibodies to prevent HIV from infecting cells in the first place. Both would be administered before a person becomes exposed to the virus.
Most modern vaccines use this antibody approach, but HIV's extreme skill at mutating makes it difficult for specifically targeted antibodies to identify and neutralize the virus.
Teams led by Dr. Dennis Burton of the Scripps Research Institute in La Jolla, California, Dr. Michel Nussenzweig at Rockefeller University in New York, Dr. Gary Nabel of NIAID's Vaccine Research Center, Haynes at Duke and others have focused on rare antibodies made by 10 to 20 percent of people with HIV that can neutralize a broad array of strains.
Researchers think a vaccine that can coax the body into making these antibodies before HIV exposure would offer a powerful foil to many forms of the virus.
Such antibodies seek out and latch on to regions of the virus that are highly "conserved," meaning they are so critical to the virus that they appear in nearly every HIV strain. By attaching to the virus they make it incapable of infecting other cells.
Until 2009, scientists had identified only a few broadly neutralizing antibodies, but in the past few years teams have found dozens.
So far, scientists have isolated the antibodies, identified what part of HIV they target and even know the exact shape they make, Koff said. Researchers are now using this information to design vaccines that prompt the immune system to make them.
"We're not there yet," Nabel said.
NIAID this month said it will spend up to $186 million over the next seven years to fund the Centers for HIV/AIDS Vaccine Immunology & Immunogen Discovery. The new consortium is focused on making vaccines that induce these protective antibodies, with major grants going to Duke and Scripps.
Nabel said no vaccine being tested today "is likely to hit it out of the park," but many researchers do feel advances in broadly neutralizing antibodies are key to developing a highly successful HIV vaccine.
"It's really a new day when we start to think about where we are with AIDS vaccines," Nabel said.
(Editing by Michele Gershberg and Prudence Crowther)
CHICAGO At an ill-fated press conference in 1984, U.S. Health and Human Services Secretary Margaret Heckler boldly predicted an effective AIDS vaccine would be available within just two years. But a string of failed attempts - punctuated by a 2007 tr
BEIRUT The Syrian government promised on Monday to ensure delivery of vaccinations and humanitarian aid across the country, after an outbreak of polio in the northeast and warnings of malnutrition in areas under military siege. Twenty-two children in
PARIS Merck and Co's failed AIDS vaccine may not have worked, but it probably did not raise the risk of infection either, doctors said Tuesday. Data analyzed after the large clinical trial was stopped in 2007 contradict earlier findings that suggeste
HONG KONG/BANGKOK An experimental AIDS vaccine that appears to be the first to protect people was mired for years in controversy, and credit for its success must go to Thailand where the trial was conducted, experts said. The trial was criticised fiv
PARIS Brief electric shocks may help the body better respond to certain kinds of experimental AIDS vaccines, U.S. researchers said on Thursday. They used a device that looks like a handgun to inject vaccine along with three brief electrical pulses to
WASHINGTON AIDS experts and advocates gathering in Vienna this weekend for a conference on the pandemic will hear about progress in protecting people from the deadly virus using drugs, and ways to affect behavior. No breakthrough news is expected on
WASHINGTON The discovery of immune system particles that attack the AIDS virus may finally open a way to make a vaccine that could protect people against the deadly and incurable infection, U.S. researchers said on Thursday. They used new technology
WASHINGTON An experimental AIDS vaccine made using two older vaccines protected volunteers, lowering the risk of infection by about a third, U.S. and Thai researchers reported on Thursday. The vaccine is a combination of Sanofi-Pasteur's ALVAC canary
PARIS Doctors who surprised the world of AIDS research with a study showing a vaccine prevented some HIV infections released details of their findings on Tuesday and said careful review showed they held up. Full details of the study, which showed the
WASHINGTON An AIDS vaccine that appears to have worked at least partly in Thailand may only temporarily protect patients, with the effects starting to wane after a year or so, researchers reported on Thursday. That may explain why results of the expe
WASHINGTON Researchers have discovered antibodies that can protect against a wide range of AIDS viruses and said they may be able to use them to design a vaccine against the fatal and incurable virus. The bodies of some people make these immune syste
Neue Forschungsergebnisse Charts ein Weg der Infektion und die Verbesserung der Immunantwort auf das Virus zu verhindern , dass rund 1,8 Millionen pro Jahr tötet PROBLEM: HIV / AIDS sterben rund 1,8 Millionen Menschen pro Jahr, und gilt als die dritt2011-09-20
VIENNA Scientists searching for the Holy Grail of a vaccine against the incurable AIDS virus say recent encouraging steps should now galvanize efforts to use limited funds in smarter ways to drive the field forward. International AIDS vaccine advocat
CHICAGO U.S. scientists have identified a genetically modified strain of mice that develop Zika, an important tool needed for testing vaccines and medicines to treat the virus that is rapidly spreading across the Americas and the Caribbean. Early tes
CHICAGO Better diagnostic tests and pressure to lower healthcare costs may finally usher in the era of personalized medicine, in which patients get drugs tailored to their genetic makeup, a new report suggests. Personalized medicine has been a resear
PARIS AIDS researchers want to expand their study of a rare group of HIV-infected people, whose immune systems naturally and mysteriously prevent the virus thriving in their bodies, to span the globe. Studies of these "elite controllers," which
GENEVA Malaria could be eliminated as a public health problem within a decade in most countries where it is now endemic, an international organization that funds the treatment and prevention of killer diseases said on Monday. The elimination of mothe2010-03-08 FUND
VIENNA Only 10 percent of countries have HIV prevention programs that are well matched to their national needs, leaving millions at risk of contracting the incurable virus, AIDS scientists said on Tuesday. The Global HIV Prevention Working Group, an
SEATTLE/LONDON (Reuters) -An experimental vaccine from GlaxoSmithKline halved the risk of African children getting malaria in a major clinical trial, making it likely to become the world's first shot against the deadly disease. Final-stage trial data
CHICAGO An experimental vaccine helped protect monkeys from an especially deadly form of the AIDS virus, raising new hope for an effective vaccine in people, U.S. researchers said on Wednesday. The vaccine reduced the risk of infection by 80 percent
- 03-301Far South, ein Rind-Paradies für Liebhaber
- 04-202Ich bin auf 100 MCG von Levothroid und manchmal schwindelig fühlen?
- 08-253Lebensmittelindustrie Soziale Verantwortung: Ein Mythos?
- 12-074"Dieses Papier sollte nicht veröffentlicht"
- 12-205Ist jemand mit dem Problem der Eltern ist mit Morphin in einer Klage ermordet oder sind sie gewesen?
- 10-226PPD zu verkaufen? Management sagt keine "Kombination" Gespräche geschieht
- 01-137Bed, Bath & Beyond recalls tissue holder on radiation worry
- 09-128Effexor & Welbutrin?
- 09-199Was ist beträchtlich Gewinn angestrebt (SGA)?
- 06-111Warum sollte ein Dermatologe oracea gegen Spironolacton verschreiben?
- 07-122Wie die Lebensmittel Lobby getötet britischen FDA
- 12-173Tastes of Heaven: Cotton Candy und andere Nahrungsmittel für Engel
- 10-224University of Minnesota Forscher verbinden tau an Alzheimer-Krankheit
- 01-0654 Gesundheitstechnologien Kosten vs. Innovation Debatte im Jahr 2012 zu fahren
- 02-206Acht Winkel-Haltung - Astavakrasana
- 04-3076 Wege zur Prävention von Gebärmutterhalskrebs
- 06-058Hidradenitis suppurativa - Ok, ich habe dies seit 12 Jahren gehabt, und jetzt nur noch herausfinden, was das ist.?
- 06-179Arten der Wachstumsfuge Frakturen
- Sollten die Ärzte sagen, wie viele?
- Wie können Ärzte rechtfertigen zu wachsen energetische Kinder amphetaminartige Aufputschmittel zu geben?
- Meine Zeit ist eine Woche zu spät, aber ich bin nicht schwanger - ist das normal?
- Eine Beule in der Straße ... Meine Beziehung scheint von meiner Angst zu leiden. Warum?
- Nutter Haemonetics im November zu verlassen
- Kaiser die großen Online-Test: Ist es Ihnen genug lieben dich gehen zu lassen?
- Mom's caffeine not linked to infant sleep problems: study
- Zeneca, Gicht Akquisitionen Takeda machen BCRX hoffnungsvoll für Gicht Drogendeal
- Insulin Regular - was passiert, wenn refridgerated Insulin zu warm wird ist es, den Patienten schaden?
- Nacken, Rücken, Bein, und Arm Schmerzen bei Autounfall. Medikamente Rat?
- Die weltweit erste Asian Fusion
- Neue Labor, Investitionen, Vorstandsmitglied setzen Miromatrix auf Zwei-Jahres-Spur für das erste Produkt
- Ich habe ungefähr eine Woche lang auf Lutera gewesen und eine Hälfte. Ich begann an einem Donnerstag habe ich verpasst, dass Montag & I?
- Mit Typ-2-Diabetes hat Paula Deen zu ändern, was sie kocht
- Sind Sie der SmartestDoc? Cleveland Clinic Partner auf das tägliche Quiz
- Prozac 4 Wochen nun eine Woche lang langsam auf 20 mg verjüngt ... noch etwas Angst fühlen?
- Crowdfunding Embodied Kognitionsforschung
- 10 Filme Gifted Kinder lieben
- WASHINGTON The U.S. Food and Drug Administration said on Tuesday silver-colored dental fillings that contain mercury are safe for patients, reversing an earlier caution against their use in certain patients, including pregnant women and children. "Wh
Wenn ich allergisch bin zu den Schalentieren, konnte ich eine allergische aus Lovaza reagieren? nahm yest & redrash Gesicht?auch Schwellungen einige zu Augenlider und Gesicht im Allgemeinen. Der Ausschlag war rot und spotchy über Nase und vor allem auf die Wangen, aber auch auf der Stirn. ----schneiden---- In Antwort auf die Marvell bei 2010-10-21 14.30 Manchmal sind die
- Die Generika - Konkurrenz zu Pozen 's ( NASDAQ: POZN ) Migränemedikament Treximet wird jetzt in Schach gehalten werden. Ein Richter in dem US - Bezirksgericht für den östlichen Bezirk von Texas hat eine erteilte einstweilige Verfügung , dass Aufträge
- NEWPORT, Kentucky -Â Xanodyne Pharmaceuticals Inc., Entwickler anda Hersteller ofa Drogen Fora Frauengesundheitsversorgung und Schmerzmanagement, abgeschlossen Hasa eine Finanzierung $ 50.000.000 Runde des Eigenkapitals. Die Runde wurde von geführt L
- Radiopharmaka Entwickler Navidea Biopharmaceuticals ( NYSE Amex: NAVB ) hat ein Abkommen unterzeichnet , dass es die Möglichkeit gibt , eine Parkinson-Krankheit - Bildgebungsmittel aus lizenzieren Alseres Pharmaceuticals . Gemäß den Bedingungen der T
- Ich habe 400 mg pro Nacht für Schlaflosigkeit genommen, aber ich bin immer noch eine schreckliche Zeit beim Einschlafen haben und ziemlich oft aufwachen. Soll ich es vor dem Zubettgehen oder früher nehmen? Ist es ein paar Wochen dauern, bevor es begi
FOOD POLIZEI AUF PATROL: Seattle beginnen Bewohner Müll Inspektion und für Lebensmittelabfälle SchönungDie Übervorteilung Hände von der großen Regierung erstrecken sich von allen Seiten wie Tintenfische uns in einer Senkgrube von trübem Wasser umgeben. Flailing unsere Arme, schwimmen wir aus ihren kontrollierenden Blick zu bekommen, aber ihre Tentakel
- So habe ich jetzt aboue 2 Wochen auf Lexapro gewesen, und würde ein Feedback mögen. Ich war es mit aniexty / ocd Gedanken zu helfen. Ich obsess auf negativ / irrational Suizidgedanken. Bevor ich auf eine negative Sache besessen zu halten verwenden, b
- Ein fitter Körper und Geist fit sind zwei Dinge, die sehr wichtig sind, um ein gesundes, glückliches und ausgeglichenes Leben zu haben. Die meisten Menschen denken, dass sie irgendeine Art von ungewöhnlichen diagnostizierbaren Krankheit haben, weil s
- Sie können über Hiatushernien gehört haben. Vielleicht ein Verwandter, Freund oder Kollegen sprach über die, die sie haben. Aber wissen Sie, was eine Hiatushernie ist, warum kann man entwickeln, was passiert, wenn haben Sie ein? Vielleicht denken Sie
- Bäcker gut gehütetes Geheimnis: Maismehl
- Minute Kliniken: Die McDonalds-Version des Gesundheitswesens?
- Wie die US-Wirtschaft zu beheben: weniger ihre Sachen kaufen, verkaufen mehr von uns
- Heute in der Forschung: Frühstück Dessert; die Finger Giving Is Hard
- California High School Kräfte Kinder Impfstoff Propagandafilm und geben "richtigen" Antworten oder bestraft zu sehen
- Inexpensive Allergie-Behandlungen
- 4 gesunde Lebensmittel Optionen für Ihre Fußball-Heckklappen
- Norspan Patch wd wie lange?
- Warum der Film Mythos der injizierenden Medikaments in das Herz ist Müll
- Ortho Tri Cyclen Lo Zeit zu stoppen?